Breast Cancer During Pregnancy Maternal and Fetal Outcomes

被引:137
|
作者
Cardonick, Elyce [2 ]
Dougherty, Rebecca [1 ]
Grana, Generosa [3 ]
Gilmandyar, Dzhamlaa [4 ]
Ghaffar, Sadia [5 ]
Usmani, Aniqa [6 ]
机构
[1] Lankenau Hosp, Dept Internal Med, Acad Hospitalist Program, Wynnewood, PA 19096 USA
[2] Univ Med & Dent New Jersey, Cooper Univ Hosp, Dept Obstet & Gynecol, Camden, NJ USA
[3] Univ Med & Dent New Jersey, Cooper Univ Hosp, Dept Hematol & Oncol, Camden, NJ USA
[4] Long Isl Jewish, New Hyde Pk, NY USA
[5] Bergen Reg Med Ctr, Paramus, NJ USA
[6] Robert Wood Johnson, New Brunswick, NJ USA
来源
CANCER JOURNAL | 2010年 / 16卷 / 01期
关键词
pregnancy; breast cancer; chemotherapy; children; CARCINOMA; CHEMOTHERAPY;
D O I
10.1097/PPO.0b013e3181ce46f9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Breast cancer is the most common malignancy occurring during pregnancy. Because more women delay childbearing, the diagnosis of cancer during pregnancy will likely increase. Case reports exist in the literature regarding the treatment of pregnant women with breast cancer, but few are prospective and few provide long-term follow-up on the neonate exposed to chemotherapy. In this report, 130 women diagnosed with breast cancer were reported to our voluntary national registry and followed up prospectively. Patient and Methods: The Cancer and Pregnancy Registry is a voluntary registry that monitors the clinical course, treatment, and disease outcome of women diagnosed with cancer during pregnancy and the perinatal and neonatal outcomes of their children. Results: Of the 130 diagnosed, 120 were diagnosed with a primary tumor, 8 with a recurrence, and 2 with a new primary cancer. Mean maternal age at diagnosis was 34.8 +/- 4.2 years. Mean gestational age at diagnosis was 13.2 +/- 8.1weeks. Gestational age was 12.8 +/- 7.8 weeks for patients with primary disease and 16.25 +/- 11 weeks for those with recurrent cancer. One hundred thirteen women were followed up for mean of 3.14 +/- 2.5 years. Of those followed up, 103 were diagnosed with primary breast cancer during pregnancy, 8 with a recurrence, and 2 with a new primary. Recurrence was reported in 30 patients at an average of 16.2 +/- 10.8 months from delivery to recurrence. Twenty-one patients are deceased with an average of 24.71 +/- 15.32 months from delivery to death. Only 42% were diagnosed with an estrogen-positive tumor and 35% of cases had a progesterone receptor-positive tumor. Human epidermal growth factor receptor 2 was positive in 25% of patients. Chemotherapy was given during pregnancy in 104 cases; the first treatment was given at a mean gestational age of 20.4 +/- 5.4 weeks. The malformation rate of exposed neonates was 3 not greater than the general population. Survival by stage for a primary diagnosis in pregnancy is as follows: stage I, 100%; stage II, 86%; stage III, 86%; and stage IV, 0%. Discussion: Pregnant women diagnosed with breast cancer can receive treatment comparable with nonpregnant women leading to a similar survival when matched for stage at diagnosis. The majority of children who were exposed to chemotherapy in utero did not demonstrate significant complications. We report the single largest cohort of women diagnosed with breast cancer during pregnancy.
引用
收藏
页码:76 / 82
页数:7
相关论文
共 50 条
  • [31] Maternal and fetal outcomes associated with vagus nerve stimulation during pregnancy
    Sabers, Anne
    Battino, Dina
    Bonizzoni, Erminio
    Craig, John
    Lindhout, Dick
    Perucca, Emilio
    Thomas, Sanjeev V.
    Tomson, Torbjorn
    Vajda, Frank
    EPILEPSY RESEARCH, 2017, 137 : 159 - 162
  • [32] Impact of previous lupus nephritis on maternal and fetal outcomes during pregnancy
    Miguel A. Saavedra
    Claudia Cruz-Reyes
    Olga Vera-Lastra
    Griselda T. Romero
    Polita Cruz-Cruz
    Rafael Arias-Flores
    Luis J. Jara
    Clinical Rheumatology, 2012, 31 : 813 - 819
  • [33] Maternal and fetal outcomes of antiepileptic treatments during pregnancy: A retrospective study
    Demiral, Gokce Zeytin
    Akin, Selin Betas
    Gunday, Ozlem Kayacik
    Sahbaz, Fatma Gulhan
    Boru, Ulku Turk
    EPILEPSY & BEHAVIOR, 2024, 158
  • [34] MATERNAL AND FETAL-OUTCOME AFTER BREAST-CANCER IN PREGNANCY
    ZEMLICKIS, D
    LISHNER, M
    DEGENDORFER, P
    PANZARELLA, T
    BURKE, B
    SUTCLIFFE, SB
    KOREN, G
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1992, 166 (03) : 781 - 787
  • [35] PREGNANCY, BREAST-CANCER RISK, AND MATERNAL-FETAL GENETICS
    JANERICH, DT
    LANCET, 1979, 1 (8128): : 1240 - 1241
  • [36] PREGNANCY, BREAST-CANCER RISK, AND MATERNAL-FETAL GENETICS
    JANERICH, DT
    LANCET, 1979, 1 (8111): : 327 - 328
  • [37] PREGNANCY, BREAST-CANCER RISK, AND MATERNAL-FETAL GENETICS
    DOLL, R
    LANCET, 1979, 1 (8115): : 559 - 559
  • [38] Maternal factors during pregnancy influencing maternal, fetal and childhood outcomes: Meet the Guest Editors
    Muglia, Louis
    Tong, Stephen
    Ozanne, Susan
    Benhalima, Katrien
    BMC MEDICINE, 2022, 20 (01)
  • [39] Scrub typhus in pregnancy: Maternal and fetal outcomes
    Rajan, Sudha J.
    Sathyendra, Sowmya
    Mathuram, Alice J.
    OBSTETRIC MEDICINE, 2016, 9 (04) : 164 - 166
  • [40] Kidney Disease and Maternal and Fetal Outcomes in Pregnancy
    Kendrick, Jessica
    Sharma, Shailendra
    Holmen, John
    Palit, Shyamal
    Nuccio, Eugene
    Chonchol, Michel
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2015, 66 (01) : 55 - 59